Dragan M Djuric

Prof. Dr. Dragan M Djuric

Institute of Medical Physiology "Richard Burian", Faculty of Medicine, University of Belgrade, Belgrade, Beograd, Serbia
orcid
Professor, MD, MS, PhD, FIACS, FIUPS, FILEP

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2015 in Archives of Medical Science
Verified
Journal Article
Open access
Maciej BanachMaciej Banach
Maciej Banach
MANFREDI RIZZOMANFREDI RIZZO
MANFREDI RIZZO
PTPeter P. Toth
Peter P. Toth
MFMichel Farnier
Michel Farnier
MDMichael H. Davidson
Michael H. Davidson
DMDimitri P. Mikhailidis
Dimitri P. Mikhailidis
Statins are one of the most commonly prescribed drugs in clinical practice. They are usually well tolerated and effectively prevent cardiovascular events. Most adverse effects associated with statin therapy are muscle-related. The recent statement of the European Atherosclerosis Society (EAS) has...

1 January 2017 in Archives of Medical Science
Verified
Journal Article
Open access
PDF file
Arrigo CiceroArrigo Cicero
Arrigo Cicero
ACAlessandro Colletti
Alessandro Colletti
Gani BajraktariGani Bajraktari
Gani Bajraktari
ODOlivier Descamps
Olivier Descamps
Dragan M DjuricDragan M Djuric
Dragan M Djuric
Maciej BanachMaciej Banach
Maciej Banach
In recent years, there has been growing interest in the possible use of nutraceuticals to improve and optimize dyslipidemia control and therapy. Based

1 July 2018 in JACC
Verified
Journal Article
Closed access
Maciej BanachMaciej Banach
Maciej Banach
APAngelo Maria Patti
Angelo Maria Patti
RGRosaria Vincenza Giglio
Rosaria Vincenza Giglio
Arrigo CiceroArrigo Cicero
Arrigo Cicero
Atanas G. AtanasovAtanas G. Atanasov
Atanas G. Atanasov
MRManfredi Rizzo
Manfredi Rizzo

30 January 2018 in Current Medicinal Chemistry
Verified
Journal Article
Closed access
MČMirjana B. Čolović
Mirjana B. Čolović
VVVesna M. Vasic
Vesna M. Vasic
Dragan M DjuricDragan M Djuric
Dragan M Djuric
DKDanijela Krstic
Danijela Krstic
Background: Sulphur is an abundant element in biological systems, which plays an important role in processes essential for life as a constituent of proteins, vitamins and other crucial biomolecules. The major source of sulphur for humans is plants being able to use inorganic sulphur in the purpose of sulphur-containing amino acids synthesis. Sulphur-containing amino acids include methionine, cysteine, homocysteine, and taurine. Methionine and cysteine are classified as proteinogenic, canonic amino acids incorporated in protein structure. Sulphur amino acids are involved in the synthesis of intracellular antioxidants such as glutathione and N-acetyl cysteine. Moreover, naturally occurring sulphur-containing ligands are effective and safe detoxifying agents, often used in order to prevent toxic metal ions effects and their accumulation in human body. Methods: Literature search for peer-reviewed articles was performed using PubMed and Scopus databases, and utilizing appropriate keywords. Results: This review is focused on sulphur-containing amino acids – methionine, cysteine, taurine, and their derivatives – glutathione and N-acetylcysteine, and their defense effects as antioxidant agents against free radicals. Additionally, the protective effects of sulphur-containing ligands against the toxic effects of heavy and transition metal ions, and their reactivation role towards the enzyme inhibition are described. Conclusion: Sulphur-containing amino acids represent a powerful part of cell antioxidant system. Thus, they are essential in the maintenance of normal cellular functions and health. In addition to their worthy antioxidant action, sulphur-containing amino acids may offer a chelating site for heavy metals. Accordingly, they may be supplemented during chelating therapy, providing beneficial effects in eliminating toxic metals.

9 March 2014 in Molecular and Cellular Biochemistry
Verified
Journal Article
Closed access
PDF file
MVMirjana Veselinovic
Mirjana Veselinovic
NBNevena Barudzic
Nevena Barudzic
MVMilena Vuletic
Milena Vuletic
VZVladimir Zivkovic
Vladimir Zivkovic
ATAleksandra Tomic-Lucic
Aleksandra Tomic-Lucic
Vladimir JakovljevicVladimir Jakovljevic
Vladimir Jakovljevic

7 April 2015 in Expert Opinion on Drug Safety
Verified
Journal Article
Open access
Maciej BanachMaciej Banach
Maciej Banach
MANFREDI RIZZOMANFREDI RIZZO
MANFREDI RIZZO
PTPeter P Toth
Peter P Toth
MFMichel Farnier
Michel Farnier
MDMichael H Davidson
Michael H Davidson
DMDimitri P Mikhailidis
Dimitri P Mikhailidis
Statins are one of the most commonly prescribed drugs in clinical practice. They are usually well tolerated and effectively prevent cardiovascular events. Most adverse effects associated with statin therapy are muscle-related. The recent statement of the European Atherosclerosis Society (EAS) has focused on statin-associated muscle symptoms (SAMS), and avoided the use of the term 'statin intolerance'. Although muscle syndromes are the most common adverse effects observed after statin therapy, excluding other side effects might underestimate the number of patients with statin intolerance, which might be observed in 10 - 15% of patients. In clinical practice, statin intolerance limits effective treatment of patients at risk of, or with, cardiovascular disease. Knowledge of the most common adverse effects of statin therapy that might cause statin intolerance and the clear definition of this phenomenon is crucial to effectively treat patients with lipid disorders. Therefore, the aim of this position paper was to suggest a unified definition of statin intolerance, and to complement the recent EAS statement on SAMS, where the pathophysiology, diagnosis and the management were comprehensively presented.